Navigation Links
Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
Date:3/17/2008

SEC in a publicly accessible document. Clinical program guidance is as of March 17, 2008 and financial guidance relating to the Company's current cash, cash equivalents and investments is as of December 31, 2007.

This press release includes forward-looking statements regarding the development of the Company's product candidates, projected clinical trial enrollment and data reporting timelines, and safety of the Company's products and technologies. Any statement describing a product candidate or Alexza's goals, expectations, intentions or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs that are intended to be safe and effective for use as therapeutics. Alexza's forward-looking statements also involve assumptions that, if they do not materialize or prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These statements are based only on facts and factors known by Alexza as of the date hereof. As a result, investors are cautioned not to rely on these forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission, including the risks under the headings "We have a history of net losses. We expect to continue to incur substantial and increasing net losses for the foreseeable future, and we may never achieve or maintain profitability." "We will need substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations." "Failure or delay in comme
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  Actavis plc (NYSE: ... received a complete response letter from the U.S. ... Drug Application (NDA) for the fixed-dose combination (FDC) ... hypertension.   Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... the receipt of a complete response letter, Actavis ...
(Date:12/24/2014)... Dec. 24, 2014  The International Trade Commission (ITC) issued ... against BMC Medical. In a notice issued on December 23, ... ResMed,s patent on its humidifier was invalid. BMC ... win". "We are very excited with the ITC,s decision in ... we have taken since the very beginning on the key ...
(Date:12/24/2014)... -- PuraMed BioScience®, Inc., (OTC Pink: PMBS), a researcher, ... products, announced it received the initial funding to begin ... relief product, for planned distribution to 1,000 medical and ... Washington State , and ... Advanced headache relief gel formulation completed, PuraMed BioScience has ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... BETHLEHEM, Pa., March 21, 2012  Particle Sciences, Inc., a ... with Pernix Therapeutics, a specialty pharmaceutical company, a new ... Mark Mitchnick, CEO of Particle Sciences, said, "There ... unmet need is in the delivery of these agents ...
... first time in state of New York, PediaVision will provide ... approximately 125 of the children at Boys & Girls Club ... York, on Thursday, March 22 beginning at 3 p.m.  ... from the Spot screening are provided with the necessary follow-up ...
Cached Medicine Technology:PediaVision to Conduct Free Screenings With "Spot" at Kips Bay Boys & Girls Club 2PediaVision to Conduct Free Screenings With "Spot" at Kips Bay Boys & Girls Club 3PediaVision to Conduct Free Screenings With "Spot" at Kips Bay Boys & Girls Club 4
(Date:12/25/2014)... 2014 This is a professional and ... Sterilizers industry with a focus on the Chinese market. ... of the Sterilizers manufacturers and is a valuable source ... in the industry. This report provides a basic overview ... technology. In this part, the report presents the company ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 ... Market Analysis to 2023” focuses on the current ... opportunities in the colorectal cancer market. Stivarga is ... of colon or rectal cancer. Boehringer Ingelheim is ... for the treatment of refractory CRC in the ...
(Date:12/25/2014)... New York, New York (PRWEB) December 25, 2014 ... of the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ... Liebhard LLP reports. According to an Order issued in ... November 20th, the Court will convene an open conference ... Federal Building and United States Courthouse in West Palm ...
(Date:12/25/2014)... the popular online supplier of wedding dresses and special occasion ... black one-shoulder cocktail dresses . In addition, all these elegant ... prices, up to 70% off. , The development ... You know, we have thousands of frequent callers in the ... can visit our website for more details. The current special ...
(Date:12/25/2014)... Angeles, CA (PRWEB) December 25, 2014 The ... Dolcemaschio was created in honor of a true 9/11 ... at two film festivals including the 24 hours of Nuremberg ... Festival in Bangladesh. , Actress, screenwriter and director ... helped produce this film together with her husband, Gregory ...
Breaking Medicine News(10 mins):Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
... , , BRONX, N.Y., Aug. 3 ... raising their risk of bone and heart disease, according to a study ... striking findings suggest that vitamin D deficiency could place millions of children ... disease. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090803/DC55348 ...
... But another study finding suggests insulin treatment could boost ... Metformin, one of the most widely used diabetes drugs, ... odds for pancreatic cancer by 60 percent, a new ... Other common treatments, including the use of insulin or ...
... ER treatments since 1990 , SUNDAY, Aug. 2 (HealthDay News) ... climbing for fun and exercise, the number of injuries related ... study on the subject. , More than 40,000 people sought ... fractures, sprains and other ailments related to rock-climbing -- a ...
... ... be joining dental sleep medicine,s top sleep and dental sleep professionals at Somnomed,s first annual ... ... Isn,t Sexy, LLC will be joining dental sleep medicine,s top sleep and dental sleep professionals ...
... cell lung cancer (NSCLC) patients over the age of ... erlotinib, Fox Chase Cancer Center researchers reported today at ... Study of Lung Cancer. "Based on our initial ... efficacious, though we,ll have to wait and see the ...
... , NASHVILLE, Tenn., Aug. 1 HCA Healthcare announces the following Webcast: , , ... Healthcare Webcast , , When: August ... http://www.videonewswire.com/event.asp?id=60459 , , How: ... the web at the address above. , , Contact: ...
Cached Medicine News:Health News:Millions Of U.S. Children Low In Vitamin D 2Health News:Metformin May Lower Diabetics' Odds for Pancreatic Cancer 2Health News:Metformin May Lower Diabetics' Odds for Pancreatic Cancer 3Health News:Rock-Climbing Injury Rate Soaring 2Health News:Laurence I. Barsh, DMD, Founder of Snoring Isn't Sexy, to speak at Somnomed's First Annual Symposium 2Health News:Fox Chase finds all-biologic regimen efficacious and well-tolerated in elderly lung cancer patients 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: